However, it is tempting to speculate that in humans (1) the degree of biological impact of somatic POLE aberrations on protein function and in turn clinical relevance appear to be cancer-specific rather than of general and equal importance and (2) a somatic mutation in one allele of POLE per se may not necessarily be sufficient to yield a specific clinically distinguishable phenotype. This evidence concerns the gene POLE and cancer.